論文

査読有り 国際誌
2018年4月16日

Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals.

Scientific reports
  • Yoshitaka Tamaki
  • ,
  • Akemi Shodai
  • ,
  • Toshifumi Morimura
  • ,
  • Ryota Hikiami
  • ,
  • Sumio Minamiyama
  • ,
  • Takashi Ayaki
  • ,
  • Ikuo Tooyama
  • ,
  • Yoshiaki Furukawa
  • ,
  • Ryosuke Takahashi
  • ,
  • Makoto Urushitani

8
1
開始ページ
6030
終了ページ
6030
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1038/s41598-018-24463-3
出版者・発行元
Nature Publishing Group

Aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) is implicated in the pathogenesis of sporadic and certain familial forms of amyotrophic lateral sclerosis (ALS), suggesting elimination of TDP-43 aggregates as a possible therapeutic strategy. Here we generated and investigated a single-chain variable fragment (scFv) derived from the 3B12A monoclonal antibody (MAb) that recognises D247 of the TDP-43 nuclear export signal, an epitope masked in the physiological state. In transfected HEK293A cells, 3B12A scFv recapitulated the affinity of the full-length MAb to mislocalised TDP-43 with a defective nuclear localising signal and to a TDP-43 inclusion mimic with cysteine-to-serine substitution at RRM1. Moreover, 3B12A scFv accelerated proteasome-mediated degradation of aggregated TDP-43, likely due to an endogenous PEST-like proteolytic signal sequence in the VH domain CDR2 region. Addition of the chaperone-mediated autophagy (CMA)-related signal to 3B12A scFv induced HSP70 transcription, further enhancing TDP-43 aggregate clearance and cell viability. The 3B12A scFv also reduced TDP-43 aggregates in embryonic mouse brain following in utero electroporation while causing no overt postnatal brain pathology or developmental anomalies. These results suggest that a misfolding-specific intrabody prone to synergistic proteolysis by proteasomal and autophagic pathways is a promising strategy for mitigation of TDP-43 proteinopathy in ALS.

リンク情報
DOI
https://doi.org/10.1038/s41598-018-24463-3
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29662239
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902603
ID情報
  • DOI : 10.1038/s41598-018-24463-3
  • ISSN : 2045-2322
  • PubMed ID : 29662239
  • PubMed Central 記事ID : PMC5902603
  • SCOPUS ID : 85045543526

エクスポート
BibTeX RIS